Get the Stockscreener App
14.99
6.24%
0.88
After Hours:
15.11
0.12
+0.80%
Arcutis Biotherapeutics Inc stock is traded at $14.99, with a volume of 5.08M.
It is up +6.24% in the last 24 hours and up +47.25% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$14.11
Open:
$14.25
24h Volume:
5.08M
Relative Volume:
2.48
Market Cap:
$1.75B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-2.7058
EPS:
-5.54
Net Cash Flow:
$-247.49M
1W Performance:
+18.12%
1M Performance:
+47.25%
6M Performance:
+81.04%
1Y Performance:
+478.76%
1-Day Range:
$14.18
$15.79
1-Week Range:
$12.63
$15.79
52-Week Range:
$2.51
$15.79
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
14.99 | 1.75B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 4.2%Time to Buy? - MarketBeat
State Street Corp Boosts Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Long Term Trading Analysis for (ARQT) - Stock Traders Daily
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 9.4%What's Next? - MarketBeat
Franklin Resources Inc. Decreases Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics Soars on Zoryve Success and Bullish Analyst Ratings - Nasdaq
Investors Purchase Large Volume of Call Options on Arcutis Biotherapeutics (NASDAQ:ARQT) - MarketBeat
Arcutis stock soars to 52-week high, hits $13.56 amid robust gains - Investing.com Canada
Arcutis Biotherapeutics (NASDAQ:ARQT) Hits New 52-Week HighHere's Why - MarketBeat
FDA Receives sNDA for Roflumilast Cream Treatment of Children with Atopic Dermatitis - MD Magazine
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Sees Large Decrease in Short Interest - MarketBeat
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis - The Manila Times
Arcutis Submits FDA Application for ZORYVE Cream After Promising Child Eczema Trial Results - StockTitan
Arcutis stock soars to 52-week high, hits $13.56 amid robust gains By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 4.8%Here's Why - MarketBeat
Point72 Asset Management L.P. Invests $2.27 Million in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Position Lessened by Jacobs Levy Equity Management Inc. - MarketBeat
How to Take Advantage of moves in (ARQT) - Stock Traders Daily
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
Arcutis Biotherapeutics Awards Equity Grants to New Employees Under Inducement Plan - StockTitan
Arcutis Biotherapeutics CEO Todd Watanabe buys $21,250 in stock - Investing.com India
Arcutis announces key executive promotions By Investing.com - Investing.com South Africa
Arcutis announces key executive promotions - Investing.com India
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - MSN
Insider Sell Alert: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus.com
Arcutis Biotherapeutics director sells $125,132 in stock - Investing.com India
Arcutis Biotherapeutics CEO Todd Watanabe buys $21,250 in stock By Investing.com - Investing.com Canada
Arcutis Biotherapeutics director sells $125,132 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics exec buys $7,766 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics exec buys $7,766 in stock - Investing.com
Arcutis Announces Promotions on Executive Management Team - The Manila Times
Arcutis Biotherapeutics Strengthens Leadership Team Following ZORYVE Portfolio Success - StockTitan
Short Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Drops By 9.9% - MarketBeat
Algert Global LLC Increases Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Arcutis Biotherapeutics Submits Roflumilast Cream 0.15% Supplemental NDA to US FDA for Eczema Treatment - Marketscreener.com
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Position Lifted by Suvretta Capital Management LLC - MarketBeat
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect? - MSN
(ARQT) Investment Analysis - Stock Traders Daily
Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy? - Zacks Investment Research
Rubric Capital Management LP Grows Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
There's Reason For Concern Over Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Massive 32% Price Jump - Simply Wall St
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Position Increased by Jennison Associates LLC - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average - MSN
Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now - MSN
Arcutis Biotherapeutics SVP sells $17,190 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics SVP sells $17,190 in stock - Investing.com India
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):